DSS Document Security Systems Inc.

Impact BioMedical to Begin Efficacy Testing of Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary - Innate Immune, Inc.

Impact BioMedical to Begin Efficacy Testing of Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary - Innate Immune, Inc.
EN
01/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Document Security Systems Inc.

 PRESS RELEASE

DSS, Inc. Announces Closing of $1.0 Million Underwritten Public Offeri...

DSS, Inc. Announces Closing of $1.0 Million Underwritten Public Offering NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $1.0 million, before deducting underwriting fees and other offering expenses payable by the Company. The offerin...

 PRESS RELEASE

DSS, Inc. Announces Pricing of $1.0 Million Underwritten Public Offeri...

DSS, Inc. Announces Pricing of $1.0 Million Underwritten Public Offering NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $1.0 million, before deducting underwriting fees and other offering expenses payable by the Company. The offering consists of 900,...

 PRESS RELEASE

DSS, Inc. Announces Launch of Proposed Public Offering

DSS, Inc. Announces Launch of Proposed Public Offering NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including packaging, wealth management, and biohealth innovation, today announced that it has commenced a public offering to offer and sell shares of its Common Stock. All of the shares of Common Stock are being offered by the Company (the “Offering”). The Company intends to use the net proceeds from the Offering for general corporate and working capital needs. The Company’s Common Stock is t...

 PRESS RELEASE

DSS, Inc.’s Subsidiary, Impact BioMedical Inc., Announces Strategic Me...

DSS, Inc.’s Subsidiary, Impact BioMedical Inc., Announces Strategic Merger NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (“DSS” or the “Company”), a multinational company operating across diverse industries including packaging, wealth management, and biohealth innovation, today announced that its subsidiary, Impact BioMedical Inc. (“Impact”), has entered into a definitive merger agreement (the “Merger Agreement”) with Dr. Ashleys Limited (“Dr. Ashleys”), a global pharmaceutical company. Under the terms of the agreement, Dr. Ashleys will acquire Impact through...

 PRESS RELEASE

DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the St...

DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating across diverse industries including packaging, real estate, and biomedical innovation, today announced financial results for the first quarter of 2025, highlighting meaningful progress in its financial repositioning and a strong foundation for corporate execution in the coming quarters. In a quarter focused on streamlining operations and financial discipline, DSS delivered significan...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch